CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home Item
Blood-Based Approaches to Counter Aging , homeJan. 31, 2025, 11:00 a.m. | Saul Villeda, Ph.D., Associate Professor, Chair, Department of Biomedical Science, University of California, San Francisco | Co-Sponsored by the Center for Exercise Medicine Research, Fralin Biomedical Research Institute
-
Home Item
Disability Identity, Inclusivity & Representation in Research , homeFeb. 14, 2025, 11:00 a.m. | Anjali Forber-Pratt, Ph.D., Director of Research, American Association on Health and Disability | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
How Big Med Drives Rising Healthcare Costs and What to Do About It , homeFeb. 20, 2025, 5:30 p.m. (Reception at 5 p.m.) | Vivian Ho, Ph.D., James A. Baker III Institute Chair in Health Economics, Baker Institute for Public Policy, Rice University | Maury Strauss Distinguished Public Lecture
-
Home Item
Addictive Nicotine and Stress Induce Convergent Mechanisms That Increase Alcohol Self‐administration , homeFeb. 21, 2025, 11:00 a.m. | John Dani, Ph.D., Professor of Neurological Sciences, Chair, Department of Neuroscience, Scientific Director, UPENN, CNS Consortium, Perlman School of Medicine, University of Pennsylvania | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
Exploring the Functional Role of Gene Variation in Nicotine and Alcohol Abuse , homeFeb. 21, 2025, 1 p.m. | Mariella De Biasi, Ph.D., Professor, Director, Program for Cholingeric Mechanisms in Addiction, Perlman School of Medicine, University of Pennsylvania | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home Item
The Relationship between Mitochondrial Function and Heart Failure , homeFeb. 28, 2025, 11:00 a.m. | Rong Tian, M.D., Ph.D., Professor, Department of Anesthesiology and Bioengineering, University of Washington | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research